Windlas Biotech growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+19.0%+20.4%+23.0%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+11.2%+20.5%+29.6%
+11.8%+2.3%+35.0%
+9.5%+4.3%+36.3%
+8.8%+3.9%+41.8%
+19.3%+21.4%+18.4%
+14.8%+12.3%+11.8%
+53.8%−37.4%+78.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

WINDLAS₹923.40

Windlas Biotech Limited

· Pharma & Health
₹ CrorePeersHESTERBIOINDOCOSAIPARENTSYNCOMFPANACEABIONGLFINEHIKALJAGSNPHARMMcap ₹1,949 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+23.0+20.4+19.0—
EBITDA Growth—+29.6+20.5+11.2—
EBIT Growth—+35.0+2.3+11.8—
Net Income Growth—+36.3+4.3+9.5—
EPS Growth—+41.8+3.9+8.8—
Total Assets Growth—+18.4+21.4+19.3—
Total Equity Growth—+11.8+12.3+14.8—
Cash from Operations Growth—+78.6-37.4+53.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.